Selective peroxisome proliferator-activated receptor ␥ (PPAR␥) modulators (SPPAR␥Ms) have been actively pursued as the next generation of insulin-sensitizing antidiabetic drugs, because the currently marketed PPAR␥ full agonists, pioglitazone and rosiglitazone, have been reported to produce serious adverse effects among patients with type 2 diabetes mellitus. We conducted extensive transcriptome profiling studies to characterize and to contrast the activities of 70 SPPAR␥Ms and seven PPAR␥ full agonists. In both 3T3-L1 adipocytes and adipose tissue from db/db mice, the SPPAR␥Ms generated attenuated and selective gene-regulatory responses, in comparison with full agonists. More importantly, SPPAR␥Ms regulated the expression of antidiabetic efficacy-associated genes to a greater extent than that of adverse effect-associated genes, whereas PPAR␥ full agonists regulated both gene sets proportionally.
Introduction
The three peroxisome proliferator-activated receptor (PPAR) isoforms, PPAR␥, PPAR␣, and PPAR␦, constitute a subclass of the nuclear receptor superfamily of ligand-modulated transcription factors (Willson et al., 2001; Berger and Moller, 2002; Francis et al., 2003) . PPAR␥ is expressed at elevated levels in adipocytes and has been shown to play a central role in regulating adipocyte differentiation, lipid metabolism, glucose homeostasis, and insulin sensitivity (Tontonoz et al., 1994; Schoonjans et al., 1996; Knouff and Auwerx, 2004; Rangwala and Lazar, 2004) . Numerous structurally distinct, synthetic, PPAR␥ ligands have been shown to be insulin-sensitizing agents (Saltiel and Olefsky, 1996; Berger and Moller, 2002; Wang and Tafuri, 2003) . Two currently marketed thiazolidinedione (TZD) drugs that have demonstrated notable insulin-sensitizing and antihyperglycemic efficacy among patients with type 2 diabetes mellitus, i.e., rosiglitazone and pioglitazone, are PPAR␥ agonists. Despite their beneficial actions, the use of these compounds has been constrained by their numerous adverse effects, including weight gain, increased adiposity, plasma volume expansion, edema, and an increased risk of congestive heart failure in human subjects, as well as cardiac hypertrophy in a variety of preclinical species (Peraza et al., 2006) . As a result of the observed limitations of TZD PPAR␥ full agonists, the need to identify and to develop novel classes of PPAR␥ ligands that could provide robust antidiabetic efficacy with diminished untoward effects became apparent.
We previously described nTZDpa, a non-TZD SPPAR␥M that binds to PPAR␥ with high affinity and, like PPAR␥ full agonists, completely displaces a radiolabeled ligand from the receptor in competition binding assays. In contrast to PPAR␥ full agonists, nTZDpa only partially activates the receptor in cellbased transcriptional activity assays and has a reduced ability to induce maximal 3T3-L1 cell adipogenesis (Berger et al., 2003) . Importantly, nTZDpa mitigates insulin resistance and hyperglycemia in obese diabetic rodents to a similar degree, compared with a potent TZD PPAR␥ full agonist, but without increasing cardiac weight and adiposity, as was observed with the latter ligand. We reported that compounds 24 and 12, two structurally distinct, non-TZD SPPAR␥Ms, are efficacious antihyperglycemic agents in diabetic rodents, with improved therapeutic indices, compared with rosiglitazone, with respect to the induction of cardiomegaly and excessive adiposity Liu et al., 2005) . In addition, we showed that SPPAR␥M5, another non-TZD ligand, has notable insulinsensitizing efficacy and a cardiovascular tolerability profile superior to that of rosiglitazone in obese, insulin-resistant rats (Chang et al., 2008) . Numerous other SPPAR␥Ms, including INT131 (structure in Motani et al., 2009 ), (S)-2-ethoxy-3- [4-(5-[4-[5-(methoxymethylisoxazol-3-yl) phenyl]-3-methylthiophen-2-yl]methoxy)phenyl]propanoic acid (PAR-1622) (Kim et al., 2009 ), (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533) (Acton et al., 2009) , balaglitazone (Larsen et al., 2008) , and dimethyl-2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2H)yl)ethoxy]benzyl}malonate (S26948) (Sohn et al., 2009) , have been identified that demonstrate effective insulin sensitization with reduced or no PPAR␥-related adverse effects in preclinical species (Zhang et al., 2007; Doshi et al., 2010) . These studies support the proposition that SPPAR␥Ms are not simply agonists with diminished maximal activity but are truly selective in their pharmacological actions.
On the basis of extensive pharmacological and genetic experimentation, it is now generally accepted that, because they are effectors of a master transcriptional regulator that is highly expressed in adipocytes, many of the major actions of PPAR␥ ligands are mediated by their ability to alter gene expression in these cells. A corollary to this theory is that PPAR␥ ligands that have unique physiological effects should have different adipocyte gene signatures. To test this proposition, we compared the global gene expression signatures of a series of PPAR␥ full agonists and SPPAR␥Ms in fully differentiated 3T3-L1 adipocytes, a well accepted in vitro model of rodent adipocytes. The results of these studies were extended and fortified by broadly examining changes in gene expression in adipose tissue of mice and rats treated with these PPAR␥ ligands. The discovery of both common and distinct gene expression patterns between PPAR␥ full agonists and SPPAR␥Ms furthered our understanding of the molecular basis for their shared efficacy but differential induction of adverse effects. Importantly, such profiling data allowed us to address the fundamental question of whether SPPAR␥Ms are merely weak PPAR␥ agonists or are truly selective nuclear receptor modulators that demonstrate distinct regulation of gene expression. The knowledge gained through these profiling studies allowed us to develop novel gene expression-based indices that can be used to screen for, to characterize, and to select optimized SPPAR␥Ms with the greatest probability of becoming T2D therapeutic agents with robust efficacy and enhanced tolerability, relative to currently marketed PPAR␥ agonists.
Materials and Methods
Compounds. SPPAR␥Ms L1 to L20 (Supplemental Table 1 ), 2-[2-(4-phenoxy-2-propylphenoxy)ethyl]indole-5-acetic acid (COOH) (Carley et al., 2004) , TZDfa (Einstein et al., 2008) , and LXR agonist 1 were provided by Merck Research Laboratories (Rahway, NJ). PPAR␣ agonist 1 was purchased from Chemsyn (Lenexa, KS). SPPAR␥M-L2, SPPAR␥M-L3, SPPAR␥M-L5, and SPPAR␥M-L14 were referred to previously as SPPAR␥M1, SPPAR␥M2, nTZDpa, and SPPAR␥M8, respectively (Einstein et al., 2008) . SPPAR␥M-L20 was referred to previously as SPPAR␥M6 (Acton et al., 2009) . Rosiglitazone was used as a bridging compound and was profiled in all batches of profiling experiments.
Cell-Based PPAR␥ Transactivation and FABP4 Assays. COS-1 cells were cultured and transactivation assays were performed as described previously (Berger et al., 1999) . Briefly, cells were transfected with a pcDNA3-hPPAR␥/GAL4 expression vector, pUAS(5X)-tk-luc reporter vector, and pCMV-lacZ, as an internal control for transactivation efficiency, by using Lipofectamine (Invitrogen, Carlsbad, CA). After 48-h exposure to compounds, cell lysates were produced, and luciferase and ␤-galactosidase activities in cell extracts were determined. Inflection points (EC 50 ) of normalized luciferase activity data were calculated with a four-parameter logistic equation.
FABP4 assays were performed as described previously (Thompson et al., 2004) . Briefly, 3T3-L1 preadipocyte cells (cell line CL-173; American Type Culture Collection, Manassas, VA) were treated with ligand for 5 days, and FABP4 mRNA expression levels were measured in cell lysates on the basis of hybridization of the mRNA to target-specific oligonucleotides that were conjugated to biotin. Streptavidinconjugated alkaline phosphatase was then used with the fluorescent alkaline phosphatase substrate StarBright Green Phosphate (SigmaAldrich, St. Louis, MO) to quantitate mRNA levels.
3T3-L1 Adipocyte Differentiation and Treatment. 3T3-L1 preadipocyte cells were induced to differentiate fully into adipocytes with a protocol described previously (Gerhold et al., 2002 national. Animals were housed in temperature-, humidity-, and light-controlled rooms (21-23°C, 47-65% humidity, and 12/12-h light/dark cycle, respectively).
Diabetic male db/db mice (The Jackson Laboratory, Bar Harbor, ME) with a C57B1/KFJ background, as described previously (Chen et al., 1996; Combs et al., 2002) , were given vehicle (0.25% methylcellulose) or test compounds, dosed at approximately 1 times and 3 to 10 times the ED 50 for glucose level decreases, once daily for 8 days through oral gavage. All animals were euthanized through CO 2 asphyxiation 6 h after the eighth dose, and the epididymal white adipose tissue (EWAT) was harvested and flash-frozen in liquid nitrogen. Serum glucose measurements were taken at the onset (before dosing, denoted as Glu_0) and 24 h after the seventh dose (Glu_7) by using a glucose Trinder assay kit (Sigma-Aldrich). The percentage glucose level correction was computed as 100 Ϫ [100 ϫ (db/dbDrug Ϫ LeanVehicle)/(db/dbVehicle Ϫ LeanVehicle)], by using Glu_7 glucose measurements. The percentage glucose level-lowering was computed as [(Glu_0 Ϫ Glu_7)/Glu_0] ϫ 100 for each individually profiled mouse.
Sprague-Dawley Rat Studies. Male Sprague-Dawley (SD) rats (Charles River Laboratories, Wilmington, MA) were treated with the vehicle (0.25% methylcellulose) or test compounds. Animals were given compound once daily for 7 days through oral gavage, at 1, 3, and 10 times the ED 50 for db/db mouse glucose level-lowering. All animals were euthanized through CO 2 asphyxiation approximately 24 h after the seventh dose, and EWAT samples were harvested and flash-frozen in liquid nitrogen. Heart and body weights were measured at the end of the study.
Microarray Profiling. The microarrays used for 3T3-L1 adipocytes and db/db mouse profiling experiments were Agilent 25K v1.2 mouse DNA microarrays (Agilent Technologies, Santa Clara, CA), which contain 23,698 probes (reporters), corresponding to 22,775 unique transcripts and 17,192 unique Entrez genes. The microarrays used for the SD rat profiling experiments were Agilent 25K v1.2 rat DNA microarrays, which contain 23,698 probes, corresponding to 22,503 unique transcripts and 11,219 unique Entrez genes. The microarrays we used contained two or three duplicate 60-mer probes targeting different sequence regions for a small proportion of genes. Because the expression associated with each of the duplicate probes was measured independently and the number of genes with duplicate probes was not large enough to change any of our conclusions, we used probe number rather than unique gene number to describe our gene signature results throughout this article.
Total RNA was prepared from the 3T3-L1 adipocytes or EWAT after homogenization by using TRIzol reagent (Invitrogen) with a PT 10/35 Polytron homogenizer (Kinematica, Bohemia, NY) and was processed by using RNeasy kits (QIAGEN, Valencia, CA), according to the manufacturer's instructions; RNA concentrations were estimated from 260-nm absorbance values. Total RNA samples were further processed in the microarray experiments as reported previously (Hughes et al., 2001) . Labeled cRNA was hybridized for 48 h on Agilent 60-mer, two-color, spotted microarrays. Individual samples from vehicle and test compound treatments were hybridized against a reference pool composed of an equal amount of cRNA from the vehicle treatment samples. Fluor-reversed pairs were constructed for each individual comparison.
Analytical Methods for Profiling Data. The raw microarray data were processed with Rosetta Resolver (Rosetta Biosoftware, Seattle, WA) and MatLab (MathWorks, Natick, MA) software by using the Rosetta error model (Weng et al., 2006) . Differences in expression were quantified as the ratio between normalized, background-corrected, intensity values for the two channels (red and green) for each spot on the array and were expressed as either log ratio (log 10 of the ratio) or fold change (the ratio itself when it was Ն1.0 and the reciprocal of the ratio otherwise) values. Data from replicates (i.e., multiple samples in the same treatment group) were weighted and combined by using an error model (Weng et al., 2006) , to quantify the significance of expression changes between the test compound and vehicle treatments. For Fig. 1 , signature genes were defined as those with error-weighted, replicate-combined, p values of Ͻ0.01 and fold change values of Ͼ1.5 for any test compound, with masking of genes with strong signals in the vehicle group. The latter genes were defined as genes with error-weighted, replicate-combined, p values of Ͻ0.01 in the vehicle group or genes with p values of Ͻ0.01 for each of the three individual vehicle self-references. Additional statistical analyses are specified in the figure legends. The expression data were uploaded to the Gene Expression Omnibus database (accession number GSE31222).
PPAR ␥ Activation Index. The statistical approach used to compute the PPAR ␥ activation index (GAI), S, for a test compound was 2 fitting, in which S was selected to minimize the function
, where X i and Xi indicate the log ratio and its error, respectively, for the ith gene for the reference compound (here, rosiglitazone) and Y i and Yi indicate the log ratio and its error, respectively, for the test compound. S is the slope from a weighted, least-squares fit of a through-the-origin line to log ratio data for the reference and test compounds. For compounds with replicate profiles, the combined GAI scores were obtained by averaging values within a batch and then averaging values across batches if the compound was profiled in more than one batch.
The probes used in the fitting were selected for their ability to discriminate between PPAR␥ full agonists and SPPAR␥Ms. The selection was performed by applying t tests to a training set consisting of profiles for two PPAR␥ full agonists (total of six profiles) and four SPPAR␥Ms (total of 12 profiles) in 3T3-L1 adipocytes. The 303 selected probes resulted from application of a threshold of p Ͻ 10 Ϫ7 to the comparison of full agonists with SPPAR␥Ms and an averaged fold change for the two PPAR␥ full agonists of Ͼ1.5, relative to vehicle. The accession codes, gene symbols, probe identifications, and probe sequences for the selected 303 probes are provided in Supplemental Table 2 .
Antidiabetic Efficacy-Associated Gene Set and Adverse Effect-Associated Gene Set. The antidiabetic efficacy-associated gene set was obtained from db/db mouse EWAT profiling experiments through the following steps. First, genes with expression levels that significantly correlated (p Ͻ 0.01) with the efficacy endpoint data (glucose level correction) were selected and then intersected with genes that exhibited robust regulation by PPAR␥ full agonists (p Ͻ 0.01 for the error-weighted, replicate-combined, log ratio and fold change of Ͼ1.2 in at least two of four high-dose PPAR␥ full agonist treatment groups and p Ͻ 0.01 and fold change of Ͼ1.3 in the 100 mg/kg rosiglitazone treatment group). A total of 610 probes were obtained through the selection. Second, a fullness score (F i ) was determined for each individually profiled animal i by using rosiglitazone at 100 mg/kg as the reference in the same 2 fitting procedure as for the GAI score but using the 610 probes from step 1 instead of the 303. Third, the ratio G i was computed by dividing the glucose level correction for animal i by the average glucose level correction for animals with 100 mg/kg rosiglitazone treatment. Fourth, the ratio R ij was calculated by dividing the log ratio of probe j with animal i by the average log ratio of probe j with animals treated with 100 mg/kg rosiglitazone. Fifth, mice that were treated with SPPAR␥Ms and displayed F i values of Ͼ0.3 were preselected, and then probes with R ij values greater than F i for Ͼ80% of the preselected animals were selected. Sixth, mice that were treated with SPPAR␥Ms and displayed glucose level correction values of Ͼ40% and glucose level-lowering values of Ͼ40% were preselected, and then probes with R ij values greater than G i for Ͼ60% of the preselected animals were selected. Seventh, 29 probes were obtained by intersecting the genes identified in steps 1, 5, and 6 above and were named the antidiabetic efficacy-associated genes.
A similar approach was applied to the SD rat profiling experiments to select the adverse effect-associated genes, by using EWAT RNA profiles and heart weight normalized by body weight as the endpoint. First, 358 probes were selected from the correlation analysis of EWAT gene expression with the normalized heart weight endpoint. Second, F i was computed for each individually profiled animal i by using the same 2 fitting method as described above. Third, the ratio W i was calculated by dividing the normalized heart weight endpoint for animal i by the average normalized heart weight endpoint for animals treated with 100 mg/kg rosiglitazone. Fourth, the ratio R ij was determined by dividing the log ratio of probe j for animal i by the average log ratio of probe j for animals treated with 100 mg/kg rosiglitazone. Fifth, rats that were treated with SPPAR␥Ms and had F i values of Ͼ0.2 were preselected, and then genes with R ij values greater than 0 and less than F i for Ն60% of the preselected animals were selected. Sixth, rats that were treated with SPPAR␥Ms and had normalized heart weights of Ͼ0.0032 were preselected, and then genes with R ij values greater than 0 and less than 50% of W i for Ն80% of the preselected animals were selected. Seventh, the intersecting genes identified from steps 1, 5, and 6 above were mapped to homologous genes on mouse microarrays. Nineteen probes were obtained through this process and were named the adverse effectassociated genes. The accession codes, gene symbols, probe identifications, and probe sequences for the selected 29 and 19 probes are provided in Supplemental Tables 3 and 4 , respectively.
Antidiabetic Efficacy-Associated Gene Score, Adverse Effect-Associated Gene Score, and Selectivity Index. The antidiabetic efficacy-associated gene score and the adverse effect-associated gene score were computed through the same method as described for the GAI score but using the aforementioned 29 and 19 selected probes, respectively. The SPPAR␥M selectivity index (SI) was obtained by subtracting the adverse effect-associated gene score from the antidiabetic efficacy-associated gene score and then dividing the result by the square root of 2. The SI is equal to the distance of each dot from the 45°line in Fig. 5, A and B .
Pathway Enrichment Analysis. Enrichment of Gene Ontology Biological Process terms in the annotation of sets of probes was tested by using Gene Set Annotator in the Merck Target and Gene Information System, which provides pathway enrichment analysis to identify gene sets in which a user-supplied set of identifiers is significantly enriched. The p values were calculated by using the hypergeometric distribution and the E values from the Bonferroniadjusted p values. Gene overlap was based on mouse database identifications. The allowed maximal and minimal gene set sizes for the pathway terms were 500 and 5, respectively. The magenta color denotes genes that were up-regulated by the ligands, compared with vehicle; the cyan color indicates genes that were down-regulated. Shown are 1812 probes that met the criteria of a p value of Ͻ0.01 and a 1.5-fold change for at least one of the eight compounds. B, log ratios for rosiglitazone versus COOH (left) and rosiglitazone versus SPPAR␥M-L3 (right), for the same 1812 probes as in A. Fig. 1A . The 1812 probes within the clustergram were selected by using a threshold of an error-weighted, replicate-combined, p value of Ͻ0.01 and a fold change of Ͼ1.5 for any compound. The PPAR␥ full agonists produced robust and highly similar gene signatures both for replicate samples for each compound and for structurally distinct compounds. For example, PPAR␥ full agonist 1 and COOH are non-TZDs, but their signatures were indistinguishable from those of the TZD full agonists rosiglitazone and TZD full agonist (Fig. 1A) . No robust, consistent, SPPAR␥M-specific effects on gene expression were observed. Notably, the SPPAR␥Ms displayed similar but attenuated gene regulation patterns, compared with the PPAR␥ full agonists (Fig. 1A) . Qualitatively, the SPPAR␥M-induced signatures seemed to be a subset of those generated by the PPAR␥ full agonists.
SPPAR␥Ms Display Attenuated and Selective Gene
To examine the gene-regulating activities of three distinct representative ligands in a different manner, we compared the expression log ratios (error-weighted averages of three replicates) of the 1812 probes for rosiglitazone versus the non-TZD PPAR␥ full agonist COOH and SPPAR␥M-L3 (Fig.  1B) . In Fig. 1B , left, the genes were generally distributed along a 45°line, which indicated that they were regulated similarly by the TZD and non-TZD PPAR␥ full agonists. In Fig. 1B , right, however, the gene expression changes were shifted counterclockwise from the 45°diagonal line, which indicated that SPPAR␥M-L3 produced an attenuated genemodulatory response, compared with rosiglitazone. Similar plots for the other SPPAR␥Ms that were profiled were essentially identical (data not shown), which supports the conclusion that, in 3T3-L1 adipocytes, SPPAR␥Ms produced analogous but attenuated gene signatures, compared with PPAR␥ full agonists.
SPPAR␥M 3T3-L1 Adipocyte Signatures Are Dominated by Genes Involved in Numerous Metabolic Pathways. We next examined and compared the gene signatures of PPAR␥ full agonists and SPPAR␥Ms. Figure 2 is a representative, three-way, Venn diagram of the signature genes for two full agonists (rosiglitazone and COOH) and SPPAR␥M-L3. The values shown are the number of probes that were significantly regulated in 3T3-L1 adipocytes by the respective compounds, compared with the vehicle reference pool (error-weighted, replicate-combined, p value of Ͻ0.01 and fold change of Ͼ1.5). With such selection criteria, the SPPAR␥M-L3 signature had a total of 367 probes, whereas the rosiglitazone and COOH signatures had totals of 1469 and 1786 probes, respectively. The intersection of the three signature sets was found to contain 318 probes; these 318 probes represented 293 unique genes. The 318 overlapping probes constituted 86.6% of the SPPAR␥M-L3 signa-TABLE 1 Names and structures of PPAR␥ full agonists and SPPAR␥Ms profiled in Fig. 1 Compound Structure Table 2 ). The same observation holds true regardless of the fold-change threshold used as the basis of comparison, as well as for other SPPAR␥Ms that we profiled in a similar manner (data not shown).
Given that PPAR␥ full agonists and SPPAR␥Ms bind and activate the same nuclear receptor and have been shown to possess comparable glucose-lowering and insulin-sensitizing efficacies (Berger et al., 2003; Chang et al., 2008) , we thought it probable that the overlapping genes would be associated with the ligands' common beneficial effects on nutrient metabolism and would be enriched in metabolic pathway functions. To test this hypothesis, we conducted Gene Ontology Biological Process term-enrichment analysis, by using Gene Set Annotator in the Merck Target and Gene Information System, for the 318 probes common to the signatures of all three compounds in Fig. 2 . Table 3 shows the top 50 terms that were enriched in this probe set (hypergeometric p Ͻ 0.002). Twenty-two of the top terms are related to nutrient metabolism, including pyruvate, acetyl-CoA, and lipid metabolism and insulin signaling. Several important lipid and glucose metabolism-regulatory genes with bona fide peroxisome proliferator response elements in their promoters, such as FABP4, phosphoenolpyruvate carboxykinase, acyl-CoA oxidase, and pyruvate dehydrogenase kinase 4, were found within the common signature. In contrast, the top 50 pathways from the enrichment analysis for the 936 probes common to the gene signatures for the two PPAR␥ full agonists but not for SPPAR␥M-L3 contained fewer metabolic pathway terms. The fact that many of the top-ranked terms for these 936 probes were related to apoptosis and blood vessel development may provide some mechanistic clues to the findings regarding hemangiomas/hemangiosarcomas or other cancers observed in 2-year, high-dose, preclinical, safety-assessment studies with some PPAR␥ full agonists and PPAR dual agonists (Center for Drug Evaluation and Research, 2008; Doshi et al., 2010) .
A Novel Gene Expression Score Can Differentiate SPPAR␥Ms from PPAR␥ Full Agonists Profiled at Saturating Doses. One important question we sought to answer was whether the 3T3-L1 adipocyte gene expression profiles obtained with saturating ligand doses could be used to distinguish quantitatively SPPAR␥Ms from PPAR␥ full agonists and from non-PPAR␥ ligands. A small group of ligand profiles was used as a training set to select genes to build a classifier, and a separate larger group was used as a testing set to evaluate the performance of the classifier. The training set consisted of profiles for saturating concentrations of two PPAR␥ full agonists and four SPPAR␥Ms, whereas the testing set consisted of 29 independent compound profiles, including five PPAR␥ full agonists, 21 SPPAR␥Ms, two PPAR␣ agonists, and one LXR agonist.
Analysis of variance, applied separately to each probe in the PPAR␥ ligand gene signatures, identified 303 probes that could best discriminate PPAR␥ full agonists from SPPAR␥Ms in the training set. These 303 probes corresponded to 291 unique genes. The magnitude of changes in the expression of these probes induced by a given ligand were consolidated into a single score by fitting a line relating the log ratio for the ligand to the log ratio for the reference compound, rosiglitazone, as described in Materials and Methods. This score was named the PPAR GAI. Figure 3A is an expression heatmap of the 303 GAI probes for all training and testing ligand profiles. The dot plot on the right shows the GAI score for each ligand treatment. When the ligands were sorted on the basis of their GAI scores, all of the PPAR␥ full agonists clustered together below the blue line, whereas all of the SPPAR␥Ms clustered above it. The profiles of an LXR agonist and two PPAR␣ agonists at the top of Fig. 3A indicated that they had little impact on the expression of the 303 probes, in line with the expectation that such ligands would not act as PPAR␥ activators and could serve as useful negative controls.
The GAI is a statistically derived score that can be used to report the degree of gene regulation induced by a PPAR␥ ligand. The GAI is a relative score, in that each compound is compared with a reference compound (in this case, rosiglitazone). Figure 3B contains the replicate-combined GAI scores for 79 profiled ligands, including 70 SPPAR␥Ms, 7 PPAR␥ full agonists, 1 PPAR␣ agonist, and 1 LXR agonist. The ligands were all tested at saturating concentrations, to ensure that they were providing their maximal transcriptional activity. The GAI scores ranged from 0 to 1. The greater the maximal transcriptional activity of a PPAR␥ ligand was, the higher its GAI score was. For TZD and non-TZD PPAR␥ full agonists, GAI scores were Ͼ0.95. In contrast, GAI scores for the various SPPAR␥Ms ranged from 0.2 to 0.82, reflecting a wide range of partial receptor activation. PPAR␣ and LXR agonists had scores of Ͻ0.1.
GAI scores for individual ligands were highly reproducible within and across different batches of profiling experiments. In general, the S.D. was Ͻ0.05 and the coefficient of variation was approximately 5 to 10%. The GAI scores for all of the ligands we tested were compared with the maximal activities they demonstrated in PPAR␥ transactivation (TA) (Fig. 4A ) and FABP4 expression (Fig. 4B) assays. These two cell-based assays were used previously to characterize the functional activity of PPAR␥ ligands (Berger et al., 1999 (Berger et al., , 2003 Thompson et al., 2004) . The overall Pearson correlation coefficient for correlation between the GAI and TA scores was 0.85 (p ϭ 1.9 ϫ 10 Ϫ22 ). The correlation between GAI and FABP4 scores was much weaker, with a correlation coefficient equal to 0.4. The correlation between TA scores and FABP4 scores demonstrated a coefficient of 0.31 (data not shown), smaller than the coefficients for the correlation of GAI and TA scores and the correlation of GAI and FABP4 scores. SPPAR␥Ms Differ from Submaximally Dosed PPAR␥ Full Agonists in Their Greater Regulation of Antidiabetic Efficacy-Associated Genes versus Adverse EffectAssociated Genes. A key question regarding SPPAR␥Ms that arises from the studies described above is whether they are merely PPAR␥ partial agonists with decreased maximal activity or are truly "selective" gene modulators that can be differentiated from submaximally dosed PPAR␥ full agonists on the basis of their distinctive gene expression profiles. We identified two gene sets to address this question. As described in Materials and Methods, the first set (29 probes) was derived from db/db mouse experiments in which the gene-regulating and glucose-lowering activities of various PPAR␥ ligands, administered at 1 and 3 times their antihyperglycemic ED 50 values, were examined. The second gene set (19 probes) was obtained from experiments using SD rats in which the effects of PPAR␥ ligands, administered at up to 10 times the db/db mouse antihyperglycemic ED 50 values, on gene expression and cardiac hypertrophy were assessed. An antidiabetic efficacy-associated gene score and an adverse effect-associated gene score for a PPAR␥ ligand could then be computed with the line-fitting approach used for the GAI, with expression data from the aforementioned 29 and 19 probes, respectively. Figure 5A provides a comparison of these two gene scores in a representative, independent, db/db mouse EWAT, gene expression profiling experiment for three PPAR␥ full agonists and three SPPAR␥Ms. All ligands except rosiglitazone were different from those profiled in the db/db data set used to select the aforementioned probes. The scores for the PPAR␥ full agonists, which were tested over a range of doses, generally fell along the 45°line, which indicated that those ligands increased efficacy and adverse effect gene expression proportionally with dose. However, the scores for Fig. 3 . PPAR␥ ligand regulation of GAI genes and resulting GAI scores. A, regulation of expression of the 303 GAI probes in 3T3-L1 adipocytes with the training (red) and testing (blue) ligands. The dot plot on the right shows the GAI score for each ligand treatment. The blue line separates the ligands into PPAR␥ full agonists and SPPAR␥Ms. The yellow line separates PPAR␥ ligands from non-PPAR␥ ligands. The profiles were generated in three independent batches of experiments, denoted E1, E2, and E3. Log ratio values are shown with the same color scheme as in the heatmap in Fig.  1 . B, replicate-combined GAI scores for seven PPAR␥ full agonists (red) and 70 SPPAR␥Ms (blue) profiled in 3T3-L1 adipocytes. The three bars at the far right are the scores for LXR agonist 1 (purple), PPAR␣ agonist 1 (green), and vehicle control (black).
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at ASPET Journals on June 21, 2017 molpharm.aspetjournals.org the SPPAR␥Ms were largely well above those for the full agonists. These data demonstrated that, unlike PPAR␥ full agonists, SPPAR␥Ms did not alter the expression of the two gene sets proportionally but preferentially regulated the antidiabetic efficacy-associated genes to a greater extent than the adverse effect-associated genes.
The selectivity of SPPAR␥Ms relative to PPAR␥ full agonists was verified by using scores calculated with the same 29-and 19-probe sets in the 10 independent batches of 3T3-L1 adipocyte profiling experiments described above, which used seven PPAR␥ full agonists and 70 SPPAR␥Ms treatments. It was found that PPAR␥ full agonists regulated the expression of both gene sets proportionally from low to intermediate to high doses, whereas SPPAR␥Ms altered the expression of the antidiabetic efficacy-associated genes to a greater extent than the adverse effect-associated genes (Fig.  5B ). SPPAR␥Ms were once again found almost exclusively above PPAR␥ full agonists in the 3T3-L1 adipocyte comparison plot.
Another novel gene expression-based score, the SPPAR␥M SI, was computed from the relative difference between the antidiabetic efficacy-associated gene score and the adverse effect-associated gene score, as described in Materials and Methods. The SI scores for all seven PPAR␥ full agonists and 70 SPPAR␥Ms profiled in 3T3-L1 adipocytes are presented in Fig. 6 . The vast majority of SPPAR␥Ms had SI scores above 0, which indicates that they regulated the expression of the antidiabetic efficacy-associated genes to a greater extent than the adverse effect-associated genes. In contrast, the seven profiled PPAR␥ full agonists generally had SI scores near or below 0, which indicates that they did not possess the same desirable selectivity as was observed for the SPPAR␥Ms. The SI scores for LXR and PPAR␣ ligands were also close to 0.
Unlike the GAI, the SI describes the relative change in expression between two gene sets; it does not depend on ligand dose. We used the SI scores to build a classifier (details not shown) to separate SPPAR␥Ms from submaximally dosed PPAR␥ full agonists, and we tested its performance with a subset of the independent, db/db mouse EWAT, gene profiling experiments. Among 38 blinded samples assayed, the SI classifier correctly identified 16 of 19 animals that Taken together, these data indicate that, in contrast to PPAR␥ full agonists, SPPAR␥Ms preferentially regulate antidiabetic efficacy-associated versus adverse effect-associated adipocyte genes. SPPAR␥Ms, although consistently inducing attenuated gene signatures, are not simply weak PPAR␥ agonists but are selective modulators of PPAR␥ gene-regulatory activity.
Discussion
We profiled a large set of PPAR␥ full agonists and SPPAR␥Ms in multiple batches of experiments, both in vitro and in vivo. In 3T3-L1 adipocyte profiling studies, we did not find robust consistent gene signatures that were oppositely regulated by PPAR␥ full agonists versus multiple SPPAR␥Ms. Similar findings were obtained in in vivo profiling studies using db/db mice and SD rats. Instead, we found that saturating concentrations of SPPAR␥Ms produced largely similar but attenuated adipocyte gene signatures, compared with PPAR␥ full agonists. This attenuation was characterized by fewer significantly regulated genes and an overall smaller magnitude of regulation of genes that demonstrated significantly altered expression.
The gene expression profiles we observed could be summarized by a single score, the GAI, which was used to quantify and to rank the maximal gene-regulatory activity of PPAR␥ ligands. When GAI scores for a group of ligands were compared with results obtained from two other cell-based, functional assays previously used to characterize the same PPAR␥ ligands (Berger et al., 2003; Thompson et al., 2004) , we found that GAI scores were highly correlated with TA scores, the maximal ligand activation of PPAR␥-GAL4 chimeric receptors transiently cotransfected into COS-1 cells with a pUAS(5X)-tk-luc reporter vector. In contrast, a stillsignificant but reduced correlation was seen between GAI scores and the maximal ligand-induced up-regulation of 3T3-L1 cell expression of the PPAR␥ target gene FABP4. We posit that the GAI is superior to both the TA and FABP4 expression scores. The GAI is derived from alterations in gene expression in 3T3-L1 adipocytes, which represent a more physiologically relevant cell system than the engineered COS-1 cells with which the TA score is derived. The GAI score is calculated from changes in the expression of numerous PPAR␥-regulated genes in fully differentiated 3T3-L1 adipocytes, rather than the expression of only the FABP4 gene in undifferentiated 3T3-L1 cells. In addition, the correlations for GAI versus TA scores and GAI versus FABP4 scores were stronger than the correlation of TA versus FABP4 scores. Therefore, it is reasonable to conclude that determination of GAI scores should be more accurate for quantitative assessment of maximal PPAR␥ ligand activity, compared with the other two methods.
All TZD and non-TZD PPAR␥ full agonists had GAI scores of ϳ1.0, similar to that of the reference compound rosiglitazone. In contrast, SPPAR␥Ms had a wide range of scores, from 0.2 to 0.82, whereas PPAR␣-and LXR-selective ligands had GAI scores of Ͻ0.1. Because the GAI scores were obtained from expression profiles obtained with saturating compound concentrations, we suggest that the magnitude of each compound's GAI score reflects the compound's intrinsic ability to activate PPAR␥-mediated gene regulation maximally. The narrow range of GAI scores observed with PPAR␥ full agonists, compared with the wide range seen with SPPAR␥Ms, and the marked gap between these score sets support the proposition that the molecular mechanisms through which these two ligand classes activate PPAR␥ are qualitatively different. It has been reported that TZD and non-TZD PPAR␥ full agonists, but not a variety of structurally distinct SPPAR␥Ms, interact directly (through hydrogen bonding) with the Tyr473 residue within helix 12 of the receptor's LBD (Einstein et al., 2008) . The binding of SPPAR␥Ms differentially stabilizes regions of the PPAR␥ LBD other than helix 12 and generates receptor conformations of decreased stability, in comparison with PPAR␥ full agonists, which leads to the formation of distinct receptortranscriptional coactivator complexes and reduced gene reg- Fig. 6 . SI scores for seven PPAR␥ full agonists (red), 70 SPPAR␥Ms (blue), vehicle control (black), PPAR␣ agonist 1 (green), and LXR agonist 1 (purple). The ligands scored in Fig. 6 and Fig. 3B are from the same data sets but sorted differently, according to the magnitude of SI and GAI scores, respectively.
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at ASPET Journals on June 21, 2017 molpharm.aspetjournals.org ulatory activity (Berger et al., 2003; Bruning et al., 2007) . The broad continuous distribution of SPPAR␥M GAI scores coincides with the previously described allosteric mechanism of SPPAR␥M activation (Bruning et al., 2007) , in which the extent of conformational change and stabilization of ␤-sheet and H3 regions within the receptor's LBD upon SPPAR␥M binding is flexible and continuous, spanning a wide dynamic range. Our studies support the observation that the expression of genes is fine-tuned, and not merely turned on and off, to meet the biological needs of cells (Meijsing et al., 2009 ). The maximal SPPAR␥M GAI score of 0.82 obtained in our studies closely coincides with the report that ligands demonstrating Ͻ80% transactivation efficacy versus rosiglitazone do not stabilize helix 12 and, therefore, a non-H12-dependent mechanism exists to control coactivator recruitment to the receptor in response to SPPAR␥Ms (Bruning et al., 2007) . Our results agree with previous observations that structurally distinct SPPAR␥Ms can display a range of efficacious and adverse effects in rodent models of T2D (Doshi et al., 2010) .
On the basis of the data described above, we hypothesized that the ideal PPAR␥ ligand would bind its receptor in a manner that would induce conformational changes favoring the formation of complexes with specific transcriptional cofactors that would optimize the regulation of target genes that control efficacy mechanisms while minimizing alterations in the expression of genes that mediate mechanism-based untoward effects. We found that SPPAR␥Ms possess an important type of gene regulation selectivity. Specifically, we demonstrated that, in comparison with PPAR␥ full agonists, SPPAR␥Ms could preferentially regulate to a greater extent a set of genes associated with antidiabetic efficacy in db/db mice, compared with a distinct gene set associated with the induction of cardiomegaly in SD rats. The genes selected for each of these two sets demonstrated changes in expression that correlated most closely with glucose level correction and cardiac hypertrophy endpoints, respectively. The greater alterations in the expression of antidiabetic efficacy-associated genes, relative to adverse effectassociated genes, by SPPAR␥Ms concur with previous observations that SPPAR␥Ms possess increased therapeutic windows, compared with PPAR␥ full agonists (Chang et al., 2008) ; the finding also agrees with the observation that SPPAR␥M signatures are dominated by genes involved in various metabolic pathways that might mediate their antidiabetic efficacy (Table 3) . It is worth noting that the two gene sets described above are those that appear to be correlated most robustly with but are not necessarily causal to the observed antidiabetic efficacy and adverse effects. Relaxing selection thresholds and/or using other selection methods might produce more genes associated with SPPAR␥M selectivity. Given that our profiling experiments included seven PPAR␥ full agonists from both TZD and non-TZD structural classes and 70 SPPAR␥Ms from multiple distinct structural classes, we think that the observed gene signatures and SPPAR␥M selectivity are not likely attributable to off-target, compound-specific effects. They almost certainly reflect the on-target, PPAR␥-mediated effects produced by different PPAR␥ ligands.
Unlike maximal transcriptional activity quantified with the GAI, the SPPAR␥M selectivity we identified with the SI was independent of ligand dose. Maximal and selective transcriptional activities, as quantified with the GAI and the SI, respectively, describe different but complementary features of PPAR␥ ligand activity. PPAR␥ full agonists display high GAI scores but no measurable selectivity, whereas SPPAR␥Ms display lower GAI scores and significant selectivity. Both GAI and SI scores can serve as important parameters for optimizing and selecting SPPAR␥Ms for clinical development. We and others have long held the view that modulating PPAR␥ activity, rather than fully activating the receptor, would be the most effective strategy for treating T2D and associated metabolic disorders (Berger et al., 2003; Cock et al., 2004) . As shown in our studies, PPAR␥ full agonists did not demonstrate selectivity in their regulation of antidiabetic efficacy-and adverse effect-associated genes over a wide dose range. It is reasonable to conclude that simply developing more-potent PPAR␥ full agonists would not lead to well tolerated therapeutic agents. In contrast, SPPAR␥Ms are likely to yield efficacious antidiabetic drugs with superior tolerability. The SPPAR␥Ms profiled here displayed consistently higher SI scores, compared with PPAR␥ full agonists, but the magnitude of these differences for the overwhelming majority of SPPAR␥Ms assayed was Յ0.2 on a log 10 scale, which indicates a maximal increase in expression of antidiabetic efficacyassociated genes versus adverse effect-associated genes of only 60%. We suggest that SPPAR␥Ms with higher SI scores might be identified and such ligands would hold the promise of demonstrating greater therapeutic indices.
In summary, SPPAR␥Ms produced attenuated gene signatures, relative to PPAR␥ full agonists, in both cultured 3T3-L1 adipocytes and rodent white adipose tissue. The gene signatures common to these two ligand classes encompassed a large proportion of the total SPPAR␥M signatures. These intersecting signatures were enriched in metabolic pathways that are likely to mediate many of the beneficial metabolic and insulinsensitizing actions of all PPAR␥ ligands. Analysis of our extensive molecular profiling experiments revealed that SPPAR␥Ms, unlike PPAR␥ full agonists, preferentially regulated an antidiabetic efficacy-associated gene set, in comparison with a distinct adverse effect-associated gene set. We also developed two novel, gene expression-based scores. The GAI quantifies a ligand's ability to stimulate maximal PPAR␥ transcriptional activity, whereas the SI quantifies a PPAR␥ ligand's induction of antidiabetic efficacy-versus adverse effect-associated genes and can differentiate SPPAR␥Ms from PPAR␥ full agonists independent of dose. The studies described here have enhanced our understanding of SPPAR␥M actions on the transcriptome and provide a potential means to identify novel PPAR␥ ligands with comparable efficacy and superior tolerability, compared with currently available, PPAR␥ agonist, antidiabetic therapeutic agents.
